AR040475A1 - Espiropiperidinas o espiropirrolidinas triciclicas - Google Patents
Espiropiperidinas o espiropirrolidinas triciclicasInfo
- Publication number
- AR040475A1 AR040475A1 AR20030102463A ARP030102463A AR040475A1 AR 040475 A1 AR040475 A1 AR 040475A1 AR 20030102463 A AR20030102463 A AR 20030102463A AR P030102463 A ARP030102463 A AR P030102463A AR 040475 A1 AR040475 A1 AR 040475A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- nitrogen
- optionally substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: m es 0, 1, 2, 3 ó 4; cada R1 representa en forma independiente halógeno, ciano, hidroxilo, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6 o sulfonamido; X representa un enlace, -CH2-, -O- o -C(O)- e Y representa un enlace, - CH2-, -O- o -C(O)-, o bien X e Y juntos representan un grupo -CH=C(CH3)- o -C(CH3)=CH-, y Z representa un enlace, -O-, -NH- o -CH2-, con la condición de que solamente uno de X; e Y, Z puede representar un enlace en cada momento y con la condición de que X e Y no representen ambos simultáneamente -O- o -C(O)-; n es 0, 1 ó 2; cada R2 representa en forma independiente halógeno o alquilo C1-6; q es 0 ó 1; R3 representa -NHC(O)R10, -C(O)NR11R12 o -COOR12a; R4, R5, R6, R7 y R8 representan cada uno en forma independiente un átomo de hidrógeno o un grupo alquilo C1-6; t es 1 ó 2; cada R9 representa en forma independiente halógeno, ciano, hidroxilo, carboxilo, alcoxi C1-6, alcoxicarbonilo C1-6, haloalquilo C1-6, o alquilo C1-6 optativamente sustituido por al menos un sustituyente seleccionado entre carboxilo y alcoxicarbonilo C1-6; R10 representa un grupo alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, adamantilo, cicloalquenilo C5-6, fenilo o un sistema de anillos heterocíclico saturado o insaturado de 5 a 10 miembros que comprende al menos un heteroátomo en el anillo seleccionado entre nitrógeno, oxígeno y azufre, cada uno de los cuales puede ser sustituido optativamente por uno o más sustituyentes seleccionados en forma independiente entre nitro, hidroxilo, oxo, halógeno, carboxilo, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, fenilo y -NHC(O)-R13 o R10 representa un grupo -NR14R15 o -O-R16; R11 y R12 representan, cada uno, en forma independiente (i) un átomo de hidrógeno, (ii) un anillo saturado o insaturado de 3 a 6 miembros que comprende optativamente al menos un heteroátomo en el anillo seleccionado entre nitrógeno, oxígeno y azufre y que optativamente comprende además un grupo puente, estando el anillo optativamente sustituido con al menos un sustituyente seleccionado entre halógeno, hidroxilo, alquilo C1-6, hidroxialquilo C1-6 y haloalquilo C1-6, (iii) un grupo alquilo C1-6 optativamente sustituido por al menos un sustituyente seleccionado entre halógeno, amino, hidroxilo, haloalquilo C1-6, carboxilo, alcoxi C1-6, alcoxicarbonilo C1-6, alquilcarbonilamino C1-6 y un anillo saturado o insaturado de 3 a 6 miembros que comprende optativamente al menos un heteroátomo en el anillo seleccionado entre nitrógeno, oxígeno y azufre y que optativamente comprende además un grupo puente, estando el anillo optativamente sustituido con al menos un sustituyente seleccionado entre halógeno, hidroxilo, oxo (=O), alquilo C1-6, hidroxialquilo C1-6 y haloalquilo C1-6, o (iv) alquilsulfonilo C1-6, o R11 y R12 junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros que optativamente comprende además un átomo de nitrógeno, oxígeno o azufre en el anillo y que optativamente está fusionado a un anillo benceno para formar un sistema de anillos de 8 a 11 miembros, estando el anillo heterocíclico o el sistema de anillos optativamente sustituido con al menos un sustituyente seleccionado entre halógeno, hidroxilo, amido, alquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, alcoxicarbonilo C1-6, haloalquilo C1-6, alquilamino C1-6, di-alquilamino (C1-6), alquilcarbonilo C1-6, alquilcarbonilamino C1-6, alquilaminocarbonilo C1-6, di-alquilaminocarbonilo C1-6, fenilo, halofenilo, fenilcarbonilo, fenilcarboniloxi e hidroxidifenilmetilo; R12a representa un átomo de hidrógeno o un grupo alquilo C1-6; R13 representa a alquilo C1-6, amino o un grupo fenilo; R14 y R15 representa cada uno en forma independiente un átomo de hidrógeno, o un grupo alquilo C1-6, alquilsulfonilo C1-6, fenilo o un sistema de anillos heterocíclico saturado o insaturado de 5 a 10 miembros que comprende al menos un heteroátomo en el anillo seleccionado entre nitrógeno, oxígeno y azufre, estando cada grupo optativamente sustituido como se ha definido anteriormente para R10, o R14 y R15 junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros que optativamente comprende además un átomo de nitrógeno, oxígeno o azufre en el anillo, estando el anillo heterocíclico optativamente sustituido por al menos un hidroxilo; y R16 representa un átomo de hidrógeno, o un grupo alquilo C1-6, fenilo o un sistema de anillos heterocíclico saturado o insaturado de 5 a 10 miembros que comprende al menos un heteroátomo en el anillo seleccionado entre nitrógeno, oxígeno y azufre, estando cada grupo optativamente sustituido como se ha definido anteriormente para R10; o una sal aceptable para uso farmacéuticamente o un solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202133A SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040475A1 true AR040475A1 (es) | 2005-04-06 |
Family
ID=20288470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102463A AR040475A1 (es) | 2002-07-08 | 2003-07-08 | Espiropiperidinas o espiropirrolidinas triciclicas |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7449475B2 (es) |
| EP (1) | EP1521757B1 (es) |
| JP (1) | JP2005537255A (es) |
| CN (2) | CN1326858C (es) |
| AR (1) | AR040475A1 (es) |
| AT (1) | ATE385235T1 (es) |
| AU (1) | AU2003243122B2 (es) |
| BR (1) | BR0312560A (es) |
| CA (1) | CA2492122A1 (es) |
| CY (1) | CY1107915T1 (es) |
| DE (1) | DE60318948T2 (es) |
| DK (1) | DK1521757T3 (es) |
| ES (1) | ES2298575T3 (es) |
| HK (1) | HK1074622A1 (es) |
| IS (1) | IS7662A (es) |
| MX (1) | MXPA05000278A (es) |
| NO (1) | NO20050635L (es) |
| NZ (1) | NZ537259A (es) |
| PL (1) | PL374877A1 (es) |
| PT (1) | PT1521757E (es) |
| RU (1) | RU2320664C2 (es) |
| SE (1) | SE0202133D0 (es) |
| TW (1) | TW200413386A (es) |
| UA (1) | UA77809C2 (es) |
| WO (1) | WO2004005295A1 (es) |
| ZA (1) | ZA200500024B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| WO2005023771A1 (ja) * | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| US20070021498A1 (en) * | 2004-10-14 | 2007-01-25 | Nafizal Hossain | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
| SE0302755D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303280D0 (sv) * | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| MXPA06014574A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Piperidinas n-sustituidas y su uso como farmaceuticos. |
| JP5154406B2 (ja) | 2005-04-13 | 2013-02-27 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8193208B2 (en) | 2005-09-09 | 2012-06-05 | Purdue Pharma L.P. | Fused and spirocycle compounds and the use thereof |
| JP5315590B2 (ja) * | 2006-02-14 | 2013-10-16 | Ｊｎｃ株式会社 | 液晶化合物、液晶組成物および液晶表示素子 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| EP2069355A4 (en) * | 2006-07-19 | 2010-03-24 | Astrazeneca Ab | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2081891A2 (en) | 2006-10-12 | 2009-07-29 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
| EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| WO2008103125A1 (en) * | 2007-02-23 | 2008-08-28 | Astrazeneca Ab | Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma |
| US20110124613A1 (en) * | 2007-02-23 | 2011-05-26 | Tomas Eriksson | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma |
| WO2008121066A1 (en) * | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
| UY31162A1 (es) * | 2007-06-20 | 2008-11-28 | Glaxo Group Ltd | Espiroindolinas como moduladores de receptores de quimioquinas |
| WO2009011655A1 (en) * | 2007-07-17 | 2009-01-22 | Astrazeneca Ab | Splropiperidine compounds, a process of their preparation, pharmaceutical compositions containing them, and their use in the treatment of airway diseases, inflammatory diseases, copd or asthma |
| WO2009011653A1 (en) * | 2007-07-17 | 2009-01-22 | Astrazeneca Ab | A process for the preparation of intermediates and their us in the synthesis of spiropiperidine compounds |
| US8536198B2 (en) * | 2007-07-24 | 2013-09-17 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| WO2009023754A1 (en) * | 2007-08-14 | 2009-02-19 | Glaxo Group Limited | Spiroindenes and spiroindanes as modulators of chemokine receptors |
| WO2009061881A1 (en) * | 2007-11-07 | 2009-05-14 | Glaxo Group Limited | Spirodihydrobenzofurans as modulators of chemokine receptors |
| JP5524083B2 (ja) * | 2008-01-30 | 2014-06-18 | セファロン、インク． | ヒスタミン−３（ｈ３）受容体リガンドとしての置換スピロ環状ピペリジン誘導体 |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010201A (en) * | 1974-04-12 | 1977-03-01 | The Upjohn Company | Organic compounds |
| US4166120A (en) * | 1978-04-14 | 1979-08-28 | American Hoechst Corporation | Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines |
| US4166119A (en) | 1978-04-14 | 1979-08-28 | American Hoechst Corporation | Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines |
| US4263317A (en) * | 1979-09-06 | 1981-04-21 | Hoechst-Roussel Pharmaceuticals, Inc. | Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s |
| US5366986A (en) | 1988-04-15 | 1994-11-22 | T Cell Sciences, Inc. | Compounds which inhibit complement and/or suppress immune activity |
| DE3930262A1 (de) | 1989-09-11 | 1991-03-21 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| PL176993B1 (pl) * | 1992-12-11 | 1999-08-31 | Merck & Co Inc | Nowe związki spiropiperydynowe oraz sposób ich wytwarzania |
| ES2119174T3 (es) * | 1993-01-28 | 1998-10-01 | Merck & Co Inc | Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas. |
| US5760054A (en) * | 1994-04-14 | 1998-06-02 | Merck & Co., Inc. | Alpha IC adrenergic receptor antagonists |
| US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| AU698028B2 (en) | 1995-05-18 | 1998-10-22 | Altana Pharma Ag | Phenyldihydrobenzofurans |
| US5931917A (en) * | 1996-09-26 | 1999-08-03 | Verifone, Inc. | System, method and article of manufacture for a gateway system architecture with system administration information accessible from a browser |
| US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| AU5803398A (en) * | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| AU6133098A (en) | 1997-01-21 | 1998-08-07 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| ATE284389T1 (de) | 1998-02-04 | 2004-12-15 | Banyu Pharma Co Ltd | Zyklische n-acylamin-derivate |
| US6151675A (en) * | 1998-07-23 | 2000-11-21 | Tumbleweed Software Corporation | Method and apparatus for effecting secure document format conversion |
| US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6212640B1 (en) * | 1999-03-25 | 2001-04-03 | Sun Microsystems, Inc. | Resources sharing on the internet via the HTTP |
| US6226752B1 (en) * | 1999-05-11 | 2001-05-01 | Sun Microsystems, Inc. | Method and apparatus for authenticating users |
| EP1224186B1 (en) | 1999-10-27 | 2003-09-24 | Millennium Pharmaceuticals, Inc. | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| AU2001243394A1 (en) * | 2000-03-02 | 2001-09-12 | Smith Kline Beecham Corporation | Compounds and methods |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| US7017175B2 (en) * | 2001-02-02 | 2006-03-21 | Opentv, Inc. | Digital television application protocol for interactive television |
| WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| WO2004041279A1 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
| WO2004050024A2 (en) * | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| US20040168184A1 (en) * | 2002-12-04 | 2004-08-26 | Jan Steenkamp | Multiple content provider user interface |
| US7966418B2 (en) * | 2003-02-21 | 2011-06-21 | Axeda Corporation | Establishing a virtual tunnel between two computer programs |
| SE0302755D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel compounds |
| US20070021498A1 (en) * | 2004-10-14 | 2007-01-25 | Nafizal Hossain | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303280D0 (sv) | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| EP1732928A2 (en) | 2004-03-29 | 2006-12-20 | Pfizer, Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
-
2002
- 2002-07-08 SE SE0202133A patent/SE0202133D0/xx unknown
-
2003
- 2003-07-03 TW TW092118200A patent/TW200413386A/zh unknown
- 2003-07-07 DE DE60318948T patent/DE60318948T2/de not_active Expired - Fee Related
- 2003-07-07 BR BR0312560-2A patent/BR0312560A/pt not_active IP Right Cessation
- 2003-07-07 NZ NZ537259A patent/NZ537259A/en unknown
- 2003-07-07 EP EP03762957A patent/EP1521757B1/en not_active Expired - Lifetime
- 2003-07-07 RU RU2004137278/04A patent/RU2320664C2/ru not_active IP Right Cessation
- 2003-07-07 AT AT03762957T patent/ATE385235T1/de not_active IP Right Cessation
- 2003-07-07 ES ES03762957T patent/ES2298575T3/es not_active Expired - Lifetime
- 2003-07-07 CA CA002492122A patent/CA2492122A1/en not_active Abandoned
- 2003-07-07 WO PCT/SE2003/001185 patent/WO2004005295A1/en active IP Right Grant
- 2003-07-07 UA UA20041210166A patent/UA77809C2/uk unknown
- 2003-07-07 PL PL03374877A patent/PL374877A1/xx not_active Application Discontinuation
- 2003-07-07 JP JP2004519472A patent/JP2005537255A/ja active Pending
- 2003-07-07 DK DK03762957T patent/DK1521757T3/da active
- 2003-07-07 PT PT03762957T patent/PT1521757E/pt unknown
- 2003-07-07 CN CNB038191466A patent/CN1326858C/zh not_active Expired - Fee Related
- 2003-07-07 MX MXPA05000278A patent/MXPA05000278A/es active IP Right Grant
- 2003-07-07 CN CNA2006101435561A patent/CN1974574A/zh active Pending
- 2003-07-07 AU AU2003243122A patent/AU2003243122B2/en not_active Ceased
- 2003-07-07 US US10/520,699 patent/US7449475B2/en not_active Expired - Fee Related
- 2003-07-08 AR AR20030102463A patent/AR040475A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 ZA ZA200500024A patent/ZA200500024B/xx unknown
- 2005-01-24 IS IS7662A patent/IS7662A/is unknown
- 2005-02-04 NO NO20050635A patent/NO20050635L/no not_active Application Discontinuation
- 2005-08-09 HK HK05106846A patent/HK1074622A1/xx not_active IP Right Cessation
-
2008
- 2008-04-03 CY CY20081100375T patent/CY1107915T1/el unknown
- 2008-11-05 US US12/265,251 patent/US20090062322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1521757A1 (en) | 2005-04-13 |
| CN1675218A (zh) | 2005-09-28 |
| TW200413386A (en) | 2004-08-01 |
| IS7662A (is) | 2005-01-24 |
| UA77809C2 (en) | 2007-01-15 |
| WO2004005295A1 (en) | 2004-01-15 |
| CA2492122A1 (en) | 2004-01-15 |
| RU2004137278A (ru) | 2005-09-10 |
| HK1074622A1 (en) | 2005-11-18 |
| ZA200500024B (en) | 2006-02-22 |
| MXPA05000278A (es) | 2005-03-31 |
| DE60318948D1 (de) | 2008-03-20 |
| DK1521757T3 (da) | 2008-05-05 |
| NZ537259A (en) | 2006-08-31 |
| AU2003243122A1 (en) | 2004-01-23 |
| ATE385235T1 (de) | 2008-02-15 |
| CY1107915T1 (el) | 2013-09-04 |
| PT1521757E (pt) | 2008-04-03 |
| PL374877A1 (en) | 2005-11-14 |
| AU2003243122B2 (en) | 2006-09-28 |
| NO20050635L (no) | 2005-03-31 |
| RU2320664C2 (ru) | 2008-03-27 |
| JP2005537255A (ja) | 2005-12-08 |
| US20090062322A1 (en) | 2009-03-05 |
| SE0202133D0 (sv) | 2002-07-08 |
| BR0312560A (pt) | 2005-05-10 |
| CN1326858C (zh) | 2007-07-18 |
| DE60318948T2 (de) | 2009-05-20 |
| ES2298575T3 (es) | 2008-05-16 |
| EP1521757B1 (en) | 2008-01-30 |
| CN1974574A (zh) | 2007-06-06 |
| US7449475B2 (en) | 2008-11-11 |
| US20050245741A1 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040475A1 (es) | Espiropiperidinas o espiropirrolidinas triciclicas | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
| AR057626A1 (es) | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor | |
| AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
| AR073586A1 (es) | Compuestos heterociclicos utiles para el tratamiento de vhc | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR046992A1 (es) | Derivados de espiro-dihidrobenzofuranos | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |